Evaxion Biotech AS (EVAX)

Name: Evaxion Biotech AS (EVAX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Evaxion Biotech AS (EVAX)

Stock Card

$3.00

$-0.01 (-0.33%)

As on 31-Aug-2026 16:00EDT

Market cap

$25 Mln

Revenue (TTM)

$8 Mln

P/E Ratio

P/B Ratio

2.8

Div. Yield

0 %

Evaxion Biotech AS (EVAX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 2.90 High: 3.07

52 Week Range

Low: 2.55 High: 12.15

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-1.1 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.6
Debt to Equity

--
Book Value

$--
EPS

$--
Face value

--
Shares outstanding

8,340,215

6 Years Aggregate

CFO

$-86.88 Mln

EBITDA

$-100.52 Mln

Net Profit

$-101.61 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Evaxion Biotech AS (EVAX)	-37.1	6.0	-25.0	9.1	-58.7	-61.0	--
BSE Sensex^*	-9.1	-1.5	2.9	-3.6	5.9	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 31-Aug-2026 | *As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022
Evaxion Biotech AS (EVAX)	12.8	-87.5	-61.4	-59.8
S&P Small-Cap 600	4.0	7.0	13.9	-17.4
BSE Sensex	9.1	8.1	18.7	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Evaxion Biotech AS (EVAX)	3.0	25.1	7.5	-8.7	-77.1	-65.1	--	2.8
Arrowhead Pharmaceuticals (ARWR)	82.4	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Cytokinetics Inc (CYTK)	70.9	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	54.6	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	106.5	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	359.4	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	540.0	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	594.0	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	350.3	9,625.4	0.0	-339.1	--	-30.6	--	7.6
Protagonist Therapeutics (PTGX)	147.8	9,339.4	282.0	82.9	-28.6	11.4	140.1	11.5

Shareholding Pattern

View Details

About Evaxion Biotech AS (EVAX)

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based... cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark. Read more

Chief Executive Officer

Mr. Christian Kanstrup M.Sc.
Chief Executive Officer

Mr. Christian Kanstrup M.Sc.
Headquarters

Horsholm
Website

https://evaxion.ai

FAQs for Evaxion Biotech AS (EVAX)

What is the current share price of Evaxion Biotech AS (EVAX) Today?

The share price of Evaxion Biotech AS (EVAX) is $3.00 (NASDAQ) as of 31-Aug-2026 16:00 EDT. Evaxion Biotech AS (EVAX) has given a return of -58.67% in the last 3 years.

What is the current PB & PE ratio of Evaxion Biotech AS (EVAX)?

Since, TTM earnings of Evaxion Biotech AS (EVAX) is negative, P/E ratio is not available.
The P/B ratio of Evaxion Biotech AS (EVAX) is 2.76 times as on 28-Aug-2026, a 47 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-3.97	1.79
2024	-5.61	-35.89
2023	-0.02	-0.10
2022	-1.84	5.15
2021	-0.10	0.07

What is the 52 Week High and Low of Evaxion Biotech AS (EVAX)?

The 52-week high and low of Evaxion Biotech AS (EVAX) are Rs 12.15 and Rs 2.55 as of 01-Sep-2026.

What is the market cap of Evaxion Biotech AS (EVAX)?

Evaxion Biotech AS (EVAX) has a market capitalisation of $ 25 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Evaxion Biotech AS (EVAX)?

Before investing in Evaxion Biotech AS (EVAX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.